Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and type 2 diabetes , a new analysis suggests. Data from a trial funded by Novo Nordisk – which produces the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for weight loss (under the brand name Wegovy) and diabetes (Ozempic) – was reanalyzed by an international team of researchers. The double-blind study involved 9,650 participants across 33 countries recruited